166 related articles for article (PubMed ID: 21270059)
1. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.
Kister I; Chamot E; Bacon JH; Cutter G; Herbert J;
Mult Scler; 2011 Jun; 17(6):725-33. PubMed ID: 21270059
[TBL] [Abstract][Full Text] [Related]
2. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
3. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Ramsaransing GS; De Keyser J
Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
[TBL] [Abstract][Full Text] [Related]
6. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
[TBL] [Abstract][Full Text] [Related]
7. Rapid disease course in African Americans with multiple sclerosis.
Kister I; Chamot E; Bacon JH; Niewczyk PM; De Guzman RA; Apatoff B; Coyle P; Goodman AD; Gottesman M; Granger C; Jubelt B; Krupp L; Lenihan M; Lublin F; Mihai C; Miller A; Munschauer FE; Perel AB; Teter BE; Weinstock-Guttman B; Zivadinov R; Herbert J
Neurology; 2010 Jul; 75(3):217-23. PubMed ID: 20644149
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
[TBL] [Abstract][Full Text] [Related]
9. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
10. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis.
Sternberg Z; Hennies C; Sternberg D; Bistulfi GL; Kazim L; Benedict RH; Chadha K; Leung C; Weinstock-Guttman B; Munschauer F
Mult Scler; 2011 Feb; 17(2):157-63. PubMed ID: 20965962
[TBL] [Abstract][Full Text] [Related]
11. Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A; Jokubaitis V; Horakova D; Kubala Havrdova E; Trojano M; Prat A; Girard M; Duquette P; Lugaresi A; Izquierdo G; Grand'Maison F; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Hupperts R; Boz C; Lechner-Scott J; Pucci E; Bergamaschi R; Van Pesch V; Ozakbas S; Granella F; Turkoglu R; Iuliano G; Spitaleri D; McCombe P; Solaro C; Slee M; Ampapa R; Soysal A; Petersen T; Sanchez-Menoyo JL; Verheul F; Prevost J; Sidhom Y; Van Wijmeersch B; Vucic S; Cristiano E; Saladino ML; Deri N; Barnett M; Olascoaga J; Moore F; Skibina O; Gray O; Fragoso Y; Yamout B; Shaw C; Singhal B; Shuey N; Hodgkinson S; Altintas A; Al-Harbi T; Csepany T; Taylor B; Hughes J; Jun JK; van der Walt A; Spelman T; Butzkueven H; Kalincik T
Mult Scler; 2020 Jan; 26(1):79-90. PubMed ID: 31397221
[TBL] [Abstract][Full Text] [Related]
12. Olfactory dysfunction in multiple sclerosis: association with secondary progression.
Silva AM; Santos E; Moreira I; Bettencourt A; Coutinho E; Gonçalves A; Pinto C; Montalban X; Cavaco S
Mult Scler; 2012 May; 18(5):616-21. PubMed ID: 22020420
[TBL] [Abstract][Full Text] [Related]
13. Increasing age at disability milestones among MS patients in the MSBase Registry.
Kister I; Chamot E; Cutter G; Bacon TE; Jokubaitis VG; Hughes SE; Gray OM; Trojano M; Izquierdo G; Grand'Maison F; Duquette P; Lugaresi A; Grammond P; Boz C; Hupperts R; Petersen T; Giuliani G; Oreja-Guevara C; Iuliano G; Lechner-Scott J; Bergamaschi R; Rio ME; Verheul F; Fiol M; Van Pesch V; Slee M; Butzkueven H; Herbert J;
J Neurol Sci; 2012 Jul; 318(1-2):94-9. PubMed ID: 22507751
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
[TBL] [Abstract][Full Text] [Related]
15. Pediatric Multiple Sclerosis Severity Score in a large US cohort.
Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T;
Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790
[TBL] [Abstract][Full Text] [Related]
16. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
[TBL] [Abstract][Full Text] [Related]
17. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada.
Saeedi J; Rieckmann P; Yee I; Tremlett H;
Mult Scler; 2012 Sep; 18(9):1239-43. PubMed ID: 22383230
[TBL] [Abstract][Full Text] [Related]
19. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
